U.S. Rep. Chris Smith (R-NJ) today commended the FDA for refusing to make the morning-after pill available over the counter and retaining its prescription-only status. Smith issued the following statement after the FDA announced its decision in a press conference today in Washington, DC: Read more

When a federal panel voted to close Fort Monmouth, it included a vague condition directing the Pentagon not to shutter the post unless it could be sure that the fort's work supporting the war on terror was not disrupted. Read more

U.S. Rep. Chris Smith (R-Hamilton), called today’s BRAC announcement “profoundly disappointing” and vowed to continue to emphasize that Ft. Monmouth is essential for both homeland security and military efforts abroad. Read more

U.S. Rep. Christopher Smith (R-4th Dist.) returned this week from the Sudan and vowed to press the Bush administration to provide new aid for African Union peacekeepers in the embattled Darfur region. Read more

U.S. Rep. Chris Smith, who returned this week from a tour of Sudanese refugee camps, says the U.S. government has helped stabilize the health of civil war victims and now must help them rebuild their lives. Read more

U.S. Rep. Chris Smith has met with leaders in Sudan, pressing them to improve human rights and to resolve violent conflict in the African nation's Darfur region. Read more

Delays in investigating the killing of dozens of Ethiopians who were protesting against alleged electoral fraud may lead to loss of evidence and testimony from victims and witnesses, a congressman from New Jersey said Wednesday. Read more

U.S. Representative Chris Smith (R-NJ) – Chairman of the House Subcommittee on Africa, Global Human Rights and International Operations – concluded the first leg of his three nation trip, departing Ethiopia en route to Sudan, where he will meet with government officials, SPLM leadership and visit refugee camps. During his trip to Ethiopia, Smith met with opposition party and government leaders, met with patients suffering from HIV-AIDS and visited a hospital treating women with fistula – a program Smith has championed in Congress. Read more

On the heels of a warning by the US Food and Drug Administration (FDA) about the dangers of RU-486, the Centers for Disease Control are now investigating into the role of RU-486 (Mifeprex) in the death of four California women. In the meantime, a drug that endangers women – there is a known total to 5 deaths in the United States and at least 3 overseas – remains available despite ongoing investigations and continued warnings that have made it clear that the drug is not safe and should not remain available. Read more

U.S. Rep. Chris Smith (R-NJ) praised the Food and Drug Administration’s (FDA’s) for creating a strengthened distribution program for Isotretinoin (Accutane) – called IPLEDGE. The program is aimed to prevent the use of the drug during pregnancy because of the significant risk of birth defects, abortions and miscarriages when taken by the mother. The FDA estimates that each year, there are more than 2,000 pregnancy exposures to this drug. Read more